{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:21:50Z","timestamp":1760548910724},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.clinthera.2009.11.010","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:59:17Z","timestamp":1264499957000},"page":"2712-2721","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: A randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00997789","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hea-Young","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geun-Kyeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Bok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2009.11.010_bib1","first-page":"5S","article-title":"Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing","volume":"43","author":"Arakawa","year":"1998","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.clinthera.2009.11.010_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1254\/jjp.49.441","article-title":"Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats","volume":"49","author":"Yamasaki","year":"1989","journal-title":"Jpn J Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.010_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-2999(87)90649-2","article-title":"Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat","volume":"142","author":"Yamasaki","year":"1987","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.010_bib4","first-page":"1462","article-title":"Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa","volume":"42","author":"Ishihara","year":"1992","journal-title":"Arzneimittelforschung."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2009.11.010_bib5","first-page":"160S","article-title":"Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells","volume":"43","author":"Aihara","year":"1998","journal-title":"Dig Dis Sci."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2009.11.010_bib6","first-page":"118S","article-title":"IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells","volume":"43","author":"Nagano","year":"1998","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.clinthera.2009.11.010_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0891-5849(94)00110-6","article-title":"Hydroxyl radical scavenging by rebamipide and related compounds: Electron paramagnetic resonance study","volume":"18","author":"Naito","year":"1995","journal-title":"Free Radic Biol Med."},{"key":"10.1016\/j.clinthera.2009.11.010_bib9","first-page":"698","article-title":"Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis","volume":"46","author":"Naito","year":"1996","journal-title":"Arzneimittelforschung."},{"key":"10.1016\/j.clinthera.2009.11.010_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1081\/DDC-200034577","article-title":"Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats","volume":"30","author":"Shin","year":"2004","journal-title":"Drug Dev Ind Pharm."},{"key":"10.1016\/j.clinthera.2009.11.010_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/00498250210130591","article-title":"Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver","volume":"32","author":"Koyama","year":"2002","journal-title":"Xenobiotica."},{"key":"10.1016\/j.clinthera.2009.11.010_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00044011-200323120-00002","article-title":"Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers","volume":"23","author":"Hasegawa","year":"2003","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.clinthera.2009.11.010_bib13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1015347219999","article-title":"Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers","volume":"47","author":"Akamatsu","year":"2002","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.clinthera.2009.11.010_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: Transport\/ absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2009.11.010_bib16","series-title":"Guideline for bioequivalence test","year":"2002"},{"key":"10.1016\/j.clinthera.2009.11.010_bib19","series-title":"Guideline on food-effect bioavailability and fed bioequivalence studies","year":"2005"},{"key":"10.1016\/j.clinthera.2009.11.010_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-4347(88)80089-6","article-title":"High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid, in human plasma and urine","volume":"434","author":"Shioya","year":"1988","journal-title":"J Chromatogr."},{"key":"10.1016\/j.clinthera.2009.11.010_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validationa revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2009.11.010_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [published correction appears in Clin Pharmacol Ther. 2004;75:124]","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.11.010_bib24","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2009.11.010_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF01059558","article-title":"An exact confidence interval from untransformed data for the ratio of two formulation means","volume":"12","author":"Locke","year":"1984","journal-title":"J Pharmacokinet Biopharm."},{"key":"10.1016\/j.clinthera.2009.11.010_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2307\/2530412","article-title":"Comparison of different methods of decisionmaking in bioequivalence assessment","volume":"37","author":"Mandallaz","year":"1981","journal-title":"Biometrics."},{"key":"10.1016\/j.clinthera.2009.11.010_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/jps.2600610845","article-title":"Use of confidence intervals in analysis of comparative bioavailability trials","volume":"61","author":"Westlake","year":"1972","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.clinthera.2009.11.010_bib28","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","year":"1992"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T19:51:14Z","timestamp":1544730674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0149291809004007"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}